Jefferies Financial Group Inc. Takes $3.47 Million Position in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC)

Key Points

• Jefferies Financial Group Inc. acquired a new stake in Bicycle Therapeutics PLC worth approximately $3.47 million, owning about 0.59% of the company as of the latest reporting period.
• Multiple institutional investors have recently modified their positions in Bicycle Therapeutics, with 86.15% of the stock currently held by institutional investors and hedge funds.
• Wall Street analysts have adjusted their target prices for Bicycle Therapeutics, with the consensus target price now at $24.22 despite mixed performance and a recent 6.2% decline in share price.

Jefferies Financial Group Inc. bought a new position in shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 408,889 shares of the company's stock, valued at approximately $3,471,000. Jefferies Financial Group Inc. owned 0.59% of Bicycle Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Baker BROS. Advisors LP boosted its stake in shares of Bicycle Therapeutics by 15.8% during the 4th quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company's stock worth $152,395,000 after buying an additional 1,485,397 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Bicycle Therapeutics by 406.2% during the 4th quarter. Point72 Asset Management L.P. now owns 4,554,900 shares of the company's stock worth $63,769,000 after buying an additional 3,655,101 shares during the last quarter. Fcpm Iii Services B.V. boosted its stake in shares of Bicycle Therapeutics by 47.5% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company's stock worth $48,333,000 after buying an additional 1,112,369 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Bicycle Therapeutics by 55.3% during the 1st quarter. Principal Financial Group Inc. now owns 631,260 shares of the company's stock worth $5,359,000 after buying an additional 224,790 shares during the last quarter. Finally, Long Focus Capital Management LLC acquired a new position in shares of Bicycle Therapeutics during the 4th quarter worth about $7,603,000. Institutional investors and hedge funds own 86.15% of the company's stock.

Bicycle Therapeutics Stock Performance

Shares of NASDAQ:BCYC traded down $0.19 during mid-day trading on Thursday, reaching $7.37. 8,541 shares of the company's stock were exchanged, compared to its average volume of 321,046. The firm has a market capitalization of $510.40 million, a price-to-earnings ratio of -2.36 and a beta of 1.44. The business's fifty day moving average price is $8.00 and its 200-day moving average price is $9.11. Bicycle Therapeutics PLC Sponsored ADR has a twelve month low of $6.10 and a twelve month high of $28.67.

Wall Street Analyst Weigh In

BCYC has been the topic of a number of research analyst reports. B. Riley dropped their target price on shares of Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Royal Bank Of Canada dropped their target price on shares of Bicycle Therapeutics from $32.00 to $25.00 and set an "outperform" rating on the stock in a report on Thursday, July 17th. Needham & Company LLC reaffirmed a "buy" rating and issued a $29.00 target price on shares of Bicycle Therapeutics in a report on Friday, May 2nd. Barclays dropped their target price on shares of Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Finally, Morgan Stanley set a $17.00 target price on shares of Bicycle Therapeutics and gave the company an "equal weight" rating in a report on Monday, May 5th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Bicycle Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $24.22.

Bicycle Therapeutics Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.